1Abd A,Tahrani Milan K,Piya Anthony H. Saxagliptin:a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus[J].J Adv Ther,2009.249-262. 被引量：1
2Argyrakopoulou G,Doupis J. DPP-4 inhibitors:from Sitagliptin monotherapy to the new Alogliptin-Pioglitazone combination therapy[J].J Adv Ther,2009.272-280. 被引量：1
3Mu James,Woods J,Zhou YP. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β cell mass and function in a rodent model of type 2 diabetes[J].Journal of Diabetes,2006.1695-1704. 被引量：1
4Akiko MY,Atsuo T,Ryosuke N. Chronic inhibition of dipeptidyl peptidase-Ⅳ with ASP8497 improved the HbA1c level,glucose intolerance,and lipid parameter level in streptozotocinnicotinamide-induced diabetic mice[J].J Naunyn-Schmiedeberg's Arch Pharmacol,2009.191-199. 被引量：1
5Lee B,Shi LH,Kassel DB. Pharmacokinetic,pharmacodynamic,and efficacy profiles of alogliptin,a novel inhibitor of dipeptidyl peptidase-4,in rats,dogs,and monkeys[J].Journal of Ethnopharmacology,2008.306-314. 被引量：1
6Flock C,Baggio LL,Longuet C. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice[J].Journal of Diabetes,2007.3006-3013. 被引量：1
7Cho JM,Jang HW,Cheon HJ. A novel dipeptidyl peptidaseⅣinhibitor DA-1229 ameliorates streptozocin-induced diabetes by increasing β cell replication and neogenesis[J].J Diabetes Res Clin Practice,2011.72-79. 被引量：1
8Vaghasiya J,Sheth N,Bhalodia Y. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes[J].J Regul Pept,2011.48-54. 被引量：1
9Jin HY,Liu WJ,Park JH. Effect of dipeptidyl peptidase Ⅳinhibitor(Vildagliptin)on peripheral nerves in streptozocin-induced diabetic rats[J].J Arch Med Res,2010.536-544. 被引量：1
10Mohan V,Yang W,Son HY. Efficacy and safety of sitaglipin in the treatment of patients with type 2 diabetes in China,India,and Korea[J].J Diabetes Res Clin Pract,2009.106-116. 被引量：1
